NGFR and melanoma: Further development of tumor-specific CD271 blocking modalities, including small molecule compounds that inhibit its function and subsequent activation of the downstream signal transduction pathways, identified in this report, can provide effective anti-melanoma targeting therapy approaches and synergize with immune-modulating agents.